Optimal trough levels in haemophilia B: Raising expectations-Reference-Cited by-同舟云学术

Optimal trough levels in haemophilia B: Raising expectations

Published:2020-08-25 Issue:6 Volume:26 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Walsh Christopher¹,Coppens Michiel²,Escobar Miguel³^ORCID,Wang Michael⁴^ORCID

Affiliation:

1. Icahn School of Medicine at Mount Sinai New York NY USA

2. Amsterdam University Medical CentersUniversity of Amsterdam Amsterdam The Netherlands

3. University of Texas Health Science Center Houston TX USA

4. University of Colorado Boulder CO USA

Funder

CSL Behring

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14098

Reference10 articles.

1. Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B

2. Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

3. MalecL CroteauS CallaghanM SidonioR.Spontaneous bleeding and poor bleeding response with extended half‐life factor IX products: A survey of select US hemophilia treatment centers. Paper presented at:ISTH2019;Melbourne Australia.

4. Excessive breakthrough bleeding in haemophilia B patients on factor IX‐albumin fusion protein prophylactic therapy: a single centre case series;Kleiboer B;Haemophilia,2019

5. Extravascular FIX and coagulation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy;Haemophilia;2024-03-10

2. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

3. Arthropathy in people with mild haemophilia: Exploring risk factors;Thrombosis Research;2022-03

4. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa;Expert Opinion on Biological Therapy;2021-07-06

5. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials;Journal of Blood Medicine;2021-07